Compare PTY & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PTY | FOLD |
|---|---|---|
| Founded | 2002 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.1B |
| IPO Year | N/A | 2007 |
| Metric | PTY | FOLD |
|---|---|---|
| Price | $12.89 | $14.21 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $29.79 |
| AVG Volume (30 Days) | 550.4K | ★ 14.8M |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | ★ 9.65% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $598,704,000.00 |
| Revenue This Year | N/A | $21.49 |
| Revenue Next Year | N/A | $18.25 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 21.28 |
| 52 Week Low | $11.92 | $5.51 |
| 52 Week High | $14.88 | $14.36 |
| Indicator | PTY | FOLD |
|---|---|---|
| Relative Strength Index (RSI) | 30.64 | 91.10 |
| Support Level | $12.85 | $10.64 |
| Resistance Level | $12.96 | $11.14 |
| Average True Range (ATR) | 0.08 | 0.36 |
| MACD | -0.00 | 0.28 |
| Stochastic Oscillator | 9.78 | 96.46 |
PIMCO Corporate & Income Opportunity Fds operates as a closed-end management investment company. It seeks to maximize total return through a combination of current income and capital appreciation. The fund invests a majority of the total assets in a combination of corporate debt obligations of varying maturities, other corporate income-producing securities, and income-producing securities of non-corporate issuers, such as U.S. Government securities, municipal securities, and mortgage-backed and other asset-backed securities issued on a public or private basis.
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.